Topic Archives: Boston Scientific (BSX)

The Second Coming of TransEnterix?

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can see all of his previous articles and most recent comments here.] Go on, admit it: you enjoyed that rambunctious little scene in Ridley Scott’s Prometheus […]

Big Bucks from Big Prostates?

[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Enjoy!] Readers not familiar with Stock Gumshoe usually arrive wondering if the salivation provoked by stock promotional writers for certain companies is justified. […]

Comments

  • Avatar

    $BSX Boston Scientific to buy Symetis for $435 mln. Valve implantation. Competition with Metronics and Edwards....

  • Dr. KSS MD PhD

    Trade notice: Exit Boston Scientific $BSX Rationale: Extended epoch of growth beginning in 2014 appears to have co...

  • Dr. KSS MD PhD

    One more sign that ardor for dealmaking is returning: Boston Scientific snaps up tiny Georgian endoscopy tech company En...

  • SoGiAm

    Author: ed226914 Comment Link: http://www.stockgumshoe.com/reviews/alternative-energy-speculator/nick-hodges-the-one-an...

  • Avatar

    NMKEF, will be the first to produce battery grade LI on a commercial scale. bought it at different times from .30 to $1...

  • Avatar

    I bought NMKEF at .30, might want to take a look at share price now, They go into full commercial production in H2, 2018...

  • Avatar

    This is a bit of an aside, but I've been thinking of putting together a tracking index of the biotechs followed here. W...

  • Dr. KSS MD PhD

    Fine coverage from Tracy Staton at Fierce of Salix's woes: http://www.fiercepharma.com/marketing/headline?utm_medium=...

  • Avatar

    TRXC Board Email addresses Paul Laviolette Chairman of the Board EMAIL paul.laviolette@svlsa.com LaViolette brings n...

  • Avatar

    Sandra, if you really suffer from chronic back pain, why not consider spinal cord stimulation with an implantable neuros...

  • Avatar

    Porter S had predicted the imminent demise of G about two years ago and had promoted Boston Scientific as a great BUY! ...

  • Dr. KSS, MD PhD

    One biotech company we semi-follow here has had the most upgrades of any in the last 90 days: Boston Scientific ($BSX). ...

  • Avatar

    Good news for Celladon? From the little I just read online about Scott Garrett it looks like he has a lot of experience...

  • Dr. KSS, MD PhD

    David B: To be fair, my mind is not closed about Medifocus. My main "issue" there is that Boston Scientific (I have shar...

  • Dr. KSS, MD, PhD

    When I first heard about the MedTronic Covidien tie up I was thinking this is like a frog marrying an apple. I was conf...

  • frank archambeau

    Paul ,try BSX Boston scientific. I have seen that teased before but I don't know of ant new developments.....

  • karmaswimswami

    I am quite confused by the Prolieve situation where it concerns Medifocus. Something doesn't add up. I have been aware o...

  • Avatar

    I've been a subscriber for almost a year. Earlier this year Porter recommended BSX (Boston Scientific) and stated that h...

  • Avatar

    Just remember one thing. Porter Stansberry is the same guy that told everyone that would listen to buy shares in Boston...

  • Avatar

    The thing that really jumps out at me is the fact that this company only has 22 million shares of stock outstanding. Wh...

  • Avatar

    Yesterday (the 19th), you guessed that the latest Stansberry "Got to Act Before Today (the 20th)"-- because of an allege...

  • Avatar

    It's Boston Scientific (BSX) -- wrote about them a few months ago when Porter started this campaign....

  • Avatar

    I took the following from an RTT News story about Johnson and Johnson that was posted on-line on October 13, 2009: "Amon...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch